JP2016501866A - 皮下脂肪生成を刺激するペプチド - Google Patents

皮下脂肪生成を刺激するペプチド Download PDF

Info

Publication number
JP2016501866A
JP2016501866A JP2015544173A JP2015544173A JP2016501866A JP 2016501866 A JP2016501866 A JP 2016501866A JP 2015544173 A JP2015544173 A JP 2015544173A JP 2015544173 A JP2015544173 A JP 2015544173A JP 2016501866 A JP2016501866 A JP 2016501866A
Authority
JP
Japan
Prior art keywords
seq
peptide
amino acid
composition
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015544173A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016501866A5 (enExample
Inventor
エバ・エイ・ターリー
セイエド・バーラム・バーラミ
ミーナ・ジェイ・ビッセル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
University of California Berkeley
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2016501866A publication Critical patent/JP2016501866A/ja
Publication of JP2016501866A5 publication Critical patent/JP2016501866A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/001—Preparations for care of the lips
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Birds (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
JP2015544173A 2012-11-25 2013-11-25 皮下脂肪生成を刺激するペプチド Pending JP2016501866A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261729626P 2012-11-25 2012-11-25
US61/729,626 2012-11-25
US201361778084P 2013-03-12 2013-03-12
US61/778,084 2013-03-12
PCT/US2013/071719 WO2014082042A2 (en) 2012-11-25 2013-11-25 Peptides that stimulate subcutaneous adipogenesis

Publications (2)

Publication Number Publication Date
JP2016501866A true JP2016501866A (ja) 2016-01-21
JP2016501866A5 JP2016501866A5 (enExample) 2017-01-12

Family

ID=49753509

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015544173A Pending JP2016501866A (ja) 2012-11-25 2013-11-25 皮下脂肪生成を刺激するペプチド

Country Status (11)

Country Link
US (2) US10766927B2 (enExample)
EP (1) EP2922869B1 (enExample)
JP (1) JP2016501866A (enExample)
KR (1) KR20150088841A (enExample)
CN (1) CN105008396A (enExample)
AU (1) AU2013347797A1 (enExample)
CA (1) CA2930117A1 (enExample)
HK (1) HK1216895A1 (enExample)
IL (1) IL239008A0 (enExample)
RU (1) RU2015123315A (enExample)
WO (1) WO2014082042A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1216895A1 (zh) 2012-11-25 2016-12-09 The Regents Of The University Of California 刺激皮下脂肪形成的肽
WO2015184125A1 (en) 2014-05-28 2015-12-03 The Regents Of The University Of California Peptides, compositions, and methods for stimulating subcutaneous adipogenesis
US10562935B2 (en) 2015-03-20 2020-02-18 London Health Sciences Centre Research Inc. Stapled peptides and uses thereof
CN107771085B (zh) * 2015-04-17 2024-09-03 斯米克控股(美国)有限公司 生物缀合物及其用途
KR102208853B1 (ko) * 2018-05-08 2021-01-28 오션펩 주식회사 주름개선 효능을 갖는 펩티드
CN113164512A (zh) * 2018-11-26 2021-07-23 韩国海洋科学技术院 刺激脂肪生成的肽、组合物和方法
CN114081861B (zh) * 2021-11-19 2023-10-31 和泓尚医(成都)生物科技有限公司 一种干细胞外泌体与复合肽抗衰制剂及其制备方法和应用
GB202211043D0 (en) * 2022-07-28 2022-09-14 Univ Birmingham Peptide agonist
WO2025059165A1 (en) * 2023-09-14 2025-03-20 University Of Florida Research Foundation, Incorporated Methods of use for rhamm-derived peptides and rhamm-derived peptide mimetics

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000512484A (ja) * 1996-04-10 2000-09-26 ユニヴァーシティ・オヴ・マニトバ ヒト・ヒアルロナン・レセプター
US20040037834A1 (en) * 2000-04-20 2004-02-26 Woloski B. Michael R. Rhamm peptide conjugates
JP2004536819A (ja) * 2001-06-11 2004-12-09 トランジション・セラピューティックス・インコーポレーテッド ウイルス性、増殖性および炎症性の疾患の治療のためにビタミンｂ１２および治療薬を用いた複合治療
US20100143382A1 (en) * 2006-11-21 2010-06-10 Turley Eva A Modulation of rhamm (cd168) for selective adipose tissue development

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA175473A (en) * 1917-01-08 1917-03-06 Clarence G. Cashman Reamer head
GB9207949D0 (en) 1992-04-09 1992-05-27 Univ Manitoba Molecular cloning of a novel hyaluronan receptor that mediates tumor cell motility
WO1994016328A1 (en) 1992-12-30 1994-07-21 Matthias Rath Synthetic oligopeptides analogous to protein signal sequences methods of identification and methods of use
GB9420740D0 (en) 1994-10-14 1994-11-30 Univ Manitoba Sequence of the hyaluronan receptor gene
US6127525A (en) 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
CA2166155C (en) 1995-12-27 2008-02-05 Eva Anne Turley Agents binding to hyaluronic acid binding domains and the use thereof
US5827740A (en) 1996-07-30 1998-10-27 Osiris Therapeutics, Inc. Adipogenic differentiation of human mesenchymal stem cells
CA2237051A1 (en) 1997-12-19 1999-06-19 Eva A. Turley Enhanced affinity hyaluronan binding peptides
US6211149B1 (en) 1998-08-03 2001-04-03 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors of formation of protease resistant prion protein
GB9811962D0 (en) 1998-06-03 1998-07-29 Janssen Pharmaceutica Nv Vertebrate homologue of UNC-53 protein of C.elegans
EP1151012A4 (en) 1998-11-19 2003-01-08 Smithkline Beecham Corp ANTAGONIST ANTIBODIES OF RHAMM
US6153432A (en) 1999-01-29 2000-11-28 Zen-Bio, Inc Methods for the differentiation of human preadipocytes into adipocytes
JP2000217576A (ja) 1999-02-02 2000-08-08 Herikkusu Kenkyusho:Kk 脂肪細胞への分化を誘導する方法、並びに脂肪細胞への分化を制御する化合物およびそのスクリーニング方法
US6864235B1 (en) 1999-04-01 2005-03-08 Eva A. Turley Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US6911429B2 (en) 1999-04-01 2005-06-28 Transition Therapeutics Inc. Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US20070116669A1 (en) * 2002-09-13 2007-05-24 Chemokine Therapeutics Corporation Interferon-inducible protein-10 (IP-10 or CXCL10) chemokine analogs for the treatment of human diseases
US7601825B2 (en) 2001-03-05 2009-10-13 Agensys, Inc. Nucleic acid and corresponding protein entitled 121P1F1 useful in treatment and detection of cancer
EP1407039A4 (en) * 2001-06-19 2005-12-21 Us Gov Health & Human Serv ANTI-ARTHROPODE VECTOR VACCINES, SELECTION METHOD AND USES THEREOF
US7387800B2 (en) 2001-08-15 2008-06-17 Meiji Dairies Corporation Sesquiterpenoid derivatives having adipocyte differentiation inhibitory effect
US20030170755A1 (en) 2001-09-26 2003-09-11 Ludwig Institute For Cancer Research Tumor-associated antigen RHAMM
AU2002332028A1 (en) 2001-10-06 2003-04-22 Boston Medical Center Corporation Preadipocyte cell strains and uses therefore
WO2003043998A1 (en) 2001-11-15 2003-05-30 Incyte San Diego Incorporated N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders, cancer, and other diseases
WO2003048358A1 (fr) 2001-12-07 2003-06-12 Nissui Pharmaceutical Co., Ltd. Gene et proteine associes a la differenciation adipocytaire
FR2834996B1 (fr) 2002-01-18 2004-12-03 Genfit S A Methode d'identification de substances capables de moduler la differenciation adipocytaire
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
SE0201863D0 (en) * 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
WO2004003545A1 (en) 2002-07-01 2004-01-08 Tufts University Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers
AU2003259285A1 (en) 2002-07-29 2004-02-16 Hmgene, Inc. Methods of identifying adipocyte specific genes, the genes identified, and their uses
EP1620061B1 (en) * 2003-04-28 2010-02-24 Sequoia Pharmaceuticals, Inc. Antiviral agents for the treatment, control and prevention of infections by coronaviruses
US20040229219A1 (en) * 2003-04-30 2004-11-18 Gallaher William R. Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)
AU2004266642A1 (en) 2003-08-12 2005-03-03 University Of Utah Research Foundation Heparin binding proteins: sensors for heparin detection
EP1677735B1 (en) 2003-10-17 2014-07-23 Joslin Diabetes Center, Inc. Methods and compositions for modulating adipocyte function
US7544661B2 (en) 2003-12-05 2009-06-09 Northwestern University Self-assembling peptide amphiphiles and related methods for growth factor delivery
CA2610791C (en) 2005-06-08 2015-12-01 Cangene Corporation Hyaluronic acid binding peptides enhance host defense against pathogenic bacteria
US20090176306A1 (en) 2005-06-10 2009-07-09 Toshio Taira Method of inducing differentiation from visceral preadipocyte to visceral adipocyte
US20070179085A1 (en) 2005-07-20 2007-08-02 Savani Rashmin C Modulation of rhamm-caveolin/lipid raft interactions to affect development, responses to tissue injury, angiogenesis, tumorigenesis, metastasis and growth factor/cytokine responses
US20070292869A1 (en) 2006-03-02 2007-12-20 Ppd Biomarker Discovery Sciences, Llc Compositions and Methods for Analyzing Renal Cancer
US8066691B2 (en) 2006-04-21 2011-11-29 Khouri Roger K Method and system for preparing soft tissue for grafting, enhancing grafting results, and grafting autologous fat to soft tissue such as the breast
WO2008047061A2 (fr) 2006-10-20 2008-04-24 Laboratoires Inneov Utilisation cosmetique par voie orale et/ou parenterale de la glucosamine eventuellement associee a au moins un compose polyphenol et composition correspondante
US20100062000A1 (en) 2006-11-21 2010-03-11 The Regents Of The University Of California Rhamm, a Co-Receptor and Its Interactions with Other Receptors in Cancer Cell Motility and the Identification of Cancer Prognitor Cell Populations
EP1967524A1 (en) * 2007-03-06 2008-09-10 Friesland Brands B.V. Methods for producing ACE-inhibitory peptides from whey and peptides obtained thereby
WO2009036246A2 (en) 2007-09-14 2009-03-19 Immunotope, Inc. Immunogens that induce cytotoxic t-lymphocytes and their use in prevention, treatment, and diagnosis of cancer
EP2197908A2 (en) 2007-09-27 2010-06-23 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
US20100290989A1 (en) 2007-10-12 2010-11-18 London Health Sciences Centre Research Inc. Compositions affecting hyaluronic acid mediated activity
WO2009061130A2 (en) 2007-11-06 2009-05-14 Procell Therapeutics Inc. Cell permeable runx3 recombinant proteins, polynucleotides encoding the same, and anticancer compositions including the same
US8216828B2 (en) 2008-05-30 2012-07-10 Corning Incorporated Assembly of cell culture vessels
EP2576597A4 (en) 2010-05-31 2013-11-06 London Health Sci Ct Res Inc HYALURONIC ACID MEDIATED MOTILITY RECEPTOR BINDING PEPTIDES (RHAMM)
US20120076810A1 (en) 2010-09-01 2012-03-29 Poland Gregory A Vaccinia virus polypeptides
CA2809847A1 (en) 2010-09-01 2012-03-08 The Regents Of The University Of California Cell culture screen for agents that control adipogenesis and myofibroblast differentiation
MX2013002303A (es) * 2010-09-07 2013-10-28 Oncotherapy Science Inc Peptidos hjurp y vacunas que incluyen los mismos.
HK1216895A1 (zh) 2012-11-25 2016-12-09 The Regents Of The University Of California 刺激皮下脂肪形成的肽
WO2015184125A1 (en) 2014-05-28 2015-12-03 The Regents Of The University Of California Peptides, compositions, and methods for stimulating subcutaneous adipogenesis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000512484A (ja) * 1996-04-10 2000-09-26 ユニヴァーシティ・オヴ・マニトバ ヒト・ヒアルロナン・レセプター
US20040037834A1 (en) * 2000-04-20 2004-02-26 Woloski B. Michael R. Rhamm peptide conjugates
JP2004536819A (ja) * 2001-06-11 2004-12-09 トランジション・セラピューティックス・インコーポレーテッド ウイルス性、増殖性および炎症性の疾患の治療のためにビタミンｂ１２および治療薬を用いた複合治療
US20100143382A1 (en) * 2006-11-21 2010-06-10 Turley Eva A Modulation of rhamm (cd168) for selective adipose tissue development

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ＪＯＵＲＮＡＬ ＯＦ ＣＥＬＬ ＳＣＩＥＮＣＥ, vol. 111, no. 12, JPN6017029483, 1998, pages 1685 - 1694, ISSN: 0003778661 *

Also Published As

Publication number Publication date
WO2014082042A2 (en) 2014-05-30
EP2922869B1 (en) 2017-09-27
AU2013347797A1 (en) 2015-07-02
KR20150088841A (ko) 2015-08-03
IL239008A0 (en) 2015-07-30
US20140179616A1 (en) 2014-06-26
US10494402B2 (en) 2019-12-03
US20150284433A1 (en) 2015-10-08
CA2930117A1 (en) 2014-05-30
CN105008396A (zh) 2015-10-28
US10766927B2 (en) 2020-09-08
EP2922869A2 (en) 2015-09-30
WO2014082042A3 (en) 2014-07-24
RU2015123315A (ru) 2017-01-10
HK1216895A1 (zh) 2016-12-09

Similar Documents

Publication Publication Date Title
US10494402B2 (en) Peptides that stimulate subcutaneous adipogenesis
JP7183164B2 (ja) Ｐａｃ１受容体作動薬（ｍａｘｃａｐ）及びその用途
CN102408470A (zh) 用作神经递质分泌抑制剂和肌肉松弛诱导物的合成肽
JP2000516579A (ja) 腸栄養性ｇｌｐ―２ペプチドのアンタゴニスト
JP2023527356A (ja) 副甲状腺機能低下症を処置するためのｐｔｈ類似体
JP5360738B2 (ja) 細胞増殖促進活性を有するペプチド
US10844102B2 (en) Peptides, compositions, and methods for stimulating subcutaneous adipogenesis
CN109890401A (zh) 改善bph症状或防止bph症状恶化或进展的方法
ITRM20130199A1 (it) Peptidi per uso dermatologico e/o cosmetico
CN102438580B (zh) 钙结合剂诱导毛发生长和/或甲生长
JP2014177464A (ja) Ｍｎｔｆペプチドの美容および皮膚科用製剤
JP7640711B2 (ja) 新規な皮膚透過性ペプチド、これを含む皮膚及び粘膜用組成物とその用途
CN110214143B (zh) 用于抑制皮肤炎症的肽及包含其的用于预防或治疗皮肤炎的组合物
JPWO2007058360A1 (ja) デスアシルグレリン及びその誘導体を有効成分とする皮膚修復促進治療剤
KR101155151B1 (ko) 성장인자?유래 펩타이드 및 이의 용도
HK40015225A (en) Composition and methods for preventing radiation injury and promoting tissue regeneration
CN110857314A (zh) 一种活性多肽、多肽衍生物、其组合物及其使用方法
KR20130032787A (ko) 심혈관 질환 예방 및 치료용 펩타이드 및 이의 용도
KR20110076864A (ko) 성장인자―유래 펩타이드 및 이의 용도

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170808

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171102

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180417